The high expression of CDCA2 in the subgroups of IDH status (Mut), WHO grade (G3), and histological type (astrocytoma and oligodendroglioma) decreased overall survival of LGG patients, allowing researchers to more accurately determine the prognosis of LGG patients and conduct targeted therapy studies for subgroups. This evidence concerns the gene CDCA2 and astrocytoma (excluding glioblastoma).